论文部分内容阅读
目的评价并比较氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效及安全性。方法将2002年8月至2006年2月于中国医科大学附属第一医院接受化疗的恶性淋巴瘤患者66例,按照治疗方案分成氟达拉滨联合米托蒽醌组(简称“氟达拉滨组”)和CHOP组,对2组的疗效及不良反应进行分析和比较。结果氟达拉滨组总有效率为81·5%,而CHOP组为48·7%;对晚期淋巴瘤、B细胞淋巴瘤及伴有血清乳酸脱氢酶(LDH)升高的淋巴瘤患者氟达拉滨组总有效率均高于CHOP组,组间比较差异均有显著性意义(P均<0·05)。氟达拉滨组血液学不良反应与CHOP组类似,而非血液学不良反应较少。结论以氟达拉滨为基础的联合化疗方案治疗初治恶性淋巴瘤以及难治、复发、晚期的恶性淋巴瘤的疗效、安全性及患者的耐受性均优于CHOP方案。
Objective To evaluate and compare the efficacy and safety of fludarabine combined with mitoxantrone and CHOP regimen in the treatment of malignant lymphoma. Methods Sixty-six patients with malignant lymphoma receiving chemotherapy from the First Affiliated Hospital of China Medical University from August 2002 to February 2006 were divided into fludarabine combined with mitoxantrone group (referred to as “Fludarabine Group ”) and CHOP group, the two groups of efficacy and adverse reactions were analyzed and compared. Results The total effective rate was 81.5% in fludarabine group and 48.7% in CHOP group. In patients with advanced lymphoma, B-cell lymphoma and lymphoma patients with elevated serum lactate dehydrogenase (LDH) The total effective rate of fludarabine group were higher than the CHOP group, the difference between the groups were significant (P all <0.05). Hemologic adverse reactions in the fludarabine group were similar to those in the CHOP group, not in the less hematologic adverse reactions. Conclusion The efficacy, safety and patient tolerance of combination chemotherapy with fludarabine in the treatment of primary malignant lymphoma and refractory, recurrent and advanced malignant lymphoma are better than CHOP regimen.